Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 11/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.64 |
| ▸ | CDK8 | P49336 | 1/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.57 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.57 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.55 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | HCK | P08631 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13558465 | 0.91 | PTK2 (0.56) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13331031 | 0.85 | PTK2 (0.50) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13558468 | 0.85 | PTK2 (0.50) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13558462 | 0.84 | KCNJ6 (0.57) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL6805489 | 0.83 | PTK2 (0.72) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13331034 | 0.83 | MAPK14 (0.49) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL1600309 | 0.81 | CDK8 (0.82) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13331032 | 0.80 | PTK2 (0.47) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL9967321 | 0.79 | CDK8 (0.78) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 | |
| SCHEMBL13741201 | 0.78 | MAPK14 (1.00) | PTK2CYP2D6CYP2C9CYP2C8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299074-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312963-A1 | P38 MAP KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | PTK2 154/4885CYP2D6 2149/4885CYP2C9 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.